Skip to contentpdufa.bio

Verekitug VALOUR

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Verekitug VALOUR is an Upstream Bio, Inc. program in severe asthma. Its next catalyst is a Readout in Q4 2027.

UPB catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Severe asthma. Sponsor: Upstream Bio, Inc. (UPB). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027UPB

Specialist biotech funds holding UPB, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors5,693,589$30.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Verekitug VALOUR's next FDA decision or readout?

The next tracked catalyst for Verekitug VALOUR is a Readout in Q4 2027.

What happened at Verekitug VALOUR's most recent FDA decision?

No FDA decision for Verekitug VALOUR is in our archive yet.

What is Verekitug VALOUR used for?

In our records Verekitug VALOUR is under review or in development for Severe asthma.

Who makes Verekitug VALOUR?

Upstream Bio, Inc. (UPB).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.